Inhibition of Nuclear Factor-κB Activation in Pancreatic β-Cells Has a Protective Effect on Allogeneic Pancreatic Islet Graft Survival

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Eldor, Roy ^a   Abel, Roy ^a   Sever, Dror ^a   Sadoun, Gad ^a   Peled, Amnon ^a   Sionov, Ronit ^b   Melloul, Danielle ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL PROTECTION; CELL SPECIFICITY; CONTROLLED STUDY; DISEASE ACTIVITY; GRAFT REJECTION; GRAFT SURVIVAL; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANIMALS; CHEMOKINE CXCL10; ENZYME ACTIVATION; GRAFT REJECTION; GRAFT SURVIVAL; H-2 ANTIGENS; INSULIN-SECRETING CELLS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, TRANSGENIC; NF-KAPPA B; NITRITES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84874338134     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056924     Document Type: Article

References (51)

1. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, et al. (2012) Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 35: 1436-1445.
2. Emamaullee JA, Shapiro AM, (2006) Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes 55: 1907-1914.
3. Matsumoto S, Noguchi H, Yonekawa Y, Okitsu T, Iwanaga Y, et al. (2006) Pancreatic islet transplantation for treating diabetes. Expert Opin Biol Ther 6: 23-37.
4. Robertson RP, (2010) Update on transplanting beta cells for reversing type 1 diabetes. Endocrinol Metab Clin North Am 39: 655-667.
5. Contreras JL, Bilbao G, Smyth CA, Jiang XL, Eckhoff DE, et al. (2001) Cytoprotection of pancreatic islets before and soon after transplantation by gene transfer of the anti-apoptotic Bcl-2 gene. Transplantation 71: 1015-1023.
6. Emamaullee JA, Rajotte RV, Liston P, Korneluk RG, Lakey JR, et al. (2005) XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 54: 2541-2548.
7. Emamaullee J, Liston P, Korneluk RG, Shapiro AM, Elliott JF, (2005) XIAP overexpression in islet beta-cells enhances engraftment and minimizes hypoxia-reperfusion injury. Am J Transplant 5: 1297-1305.
8. Plesner A, Liston P, Tan R, Korneluk RG, Verchere CB, (2005) The X-linked inhibitor of apoptosis protein enhances survival of murine islet allografts. Diabetes 54: 2533-2540.
9. Plesner A, Soukhatcheva G, Korneluk RG, Verchere CB, (2010) XIAP inhibition of beta-cell apoptosis reduces the number of islets required to restore euglycemia in a syngeneic islet transplantation model. Islets 2: 18-23.
10. Qin J, Jiao Y, Chen X, Zhou S, Liang C, et al. (2009) Overexpression of suppressor of cytokine signaling 1 in islet grafts results in anti-apoptotic effects and prolongs graft survival. Life Sci 84: 810-816.
11. Grey ST, Longo C, Shukri T, Patel VI, Csizmadia E, et al. (2003) Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. J Immunol 170: 6250-6256.
12. Emamaullee JA, Stanton L, Schur C, Shapiro AM, (2007) Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 56: 1289-1298.
13. Emamaullee JA, Davis J, Pawlick R, Toso C, Merani S, et al. (2008) The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes 57: 1556-1566.
14. Rivas-Carrillo JD, Soto-Gutierrez A, Navarro-Alvarez N, Noguchi H, Okitsu T, et al. (2007) Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice. Diabetes 56: 1259-1267.
15. Takahashi T, Matsumoto S, Matsushita M, Kamachi H, Tsuruga Y, et al. (2010) Donor pretreatment with DHMEQ improves islet transplantation. J Surg Res 163: e23-34.
16. Rink JS, Chen X, Zhang X, Kaufman DB, (2012) Conditional and specific inhibition of NF-kappaB in mouse pancreatic beta cells prevents cytokine-induced deleterious effects and improves islet survival posttransplant. Surgery 151: 330-339.
17. Gao Q, Ma LL, Gao X, Yan W, Williams P, et al. (2010) TLR4 mediates early graft failure after intraportal islet transplantation. Am J Transplant 10: 1588-1596.
18. Yang H, Thomas D, Boffa DJ, Ding R, Li B, et al. (2002) Enforced c-REL deficiency prolongs survival of islet allografts1. Transplantation 74: 291-298.
19. Eldor R, Yeffet A, Baum K, Doviner V, Amar D, et al. (2006) Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci U S A 103: 5072-5077.
20. Eldor R, Baum K, Abel R, Sever D, Melloul D, (2009) The ToI-beta transgenic mouse: a model to study the specific role of NF-kappaB in beta-cells. Diabetes Res Clin Pract 86 (Suppl 1): S7-14.
21. Poff JA, Allen CT, Traughber B, Colunga A, Xie J, et al. (2008) Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology 248: 485-491.
22. Goldberg A, Parolini M, Chin BY, Czismadia E, Otterbein LE, et al. (2007) Toll-like receptor 4 suppression leads to islet allograft survival. Faseb J 21: 2840-2848.
23. Bock T, Pakkenberg B, Buschard K, (2003) Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52: 1716-1722.
24. Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T, (2012) The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice. J Endocrinol 214: 381-387.
25. Baker MS, Chen X, Rotramel AR, Nelson JJ, Lu B, et al. (2003) Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 134: 126-133.
26. Chen C, Moreno R, Samikannu B, Bretzel RG, Schmitz ML, et al. (2010) Improved Intraportal Islet Transplantation Outcome by Systemic IKK-beta Inhibition: NF-kappaB Activity in Pancreatic Islets Depends on Oxygen Availability. Am J Transplant 11: 215-224.
27. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P, (2006) The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol 26: 487-498.
28. Karin M, Ben-Neriah Y, (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663.
29. Karin M, Lin A, (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227.
30. Perkins ND, (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62.
31. Giannoukakis N, Rudert WA, Trucco M, Robbins PD, (2000) Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. J Biol Chem 275: 36509-36513.
32. Baker MS, Chen X, Cao XC, Kaufman DB, (2001) Expression of a dominant negative inhibitor of NF-kappaB protects MIN6 beta-cells from cytokine-induced apoptosis. J Surg Res 97: 117-122.
33. Eizirik DL, Mandrup-Poulsen T, (2001) A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44: 2115-2133.
34. Heimberg H, Heremans Y, Jobin C, Leemans R, Cardozo AK, et al. (2001) Inhibition of cytokine-induced NF-kappaB activation by adenovirus- mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis. Diabetes 50: 2219-2224.
35. Mandrup-Poulsen T, (2003) Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 66: 1433-1440.
36. Melloul D, (2008) Role of NF-kappaB in beta-cell death. Biochem Soc Trans 36: 334-339.
37. Ortis F, Pirot P, Naamane N, Kreins AY, Rasschaert J, et al. (2008) Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia 51: 1213-1225.
38. Zhao Y, Krishnamurthy B, Mollah ZU, Kay TW, Thomas HE, (2011) NF-kappaB in Type 1 Diabetes. Inflamm Allergy Drug Targets 10: 208-217.
39. Ortis F, Cardozo AK, Crispim D, Storling J, Mandrup-Poulsen T, et al. (2006) Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappaB activation. Mol Endocrinol 20: 1867-1879.
40. Ou D, Wang X, Metzger DL, Robbins M, Huang J, et al. (2005) Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB. Hum Immunol 66: 799-809.
41. Rehman KK, Bertera S, Bottino R, Balamurugan AN, Mai JC, et al. (2003) Protection of islets by in situ peptide-mediated transduction of the Ikappa B kinase inhibitor Nemo-binding domain peptide. J Biol Chem 278: 9862-9868.
42. Cottet S, Dupraz P, Hamburger F, Dolci W, Jaquet M, et al. (2002) cFLIP protein prevents tumor necrosis factor-alpha-mediated induction of caspase-8-dependent apoptosis in insulin-secreting betaTc-Tet cells. Diabetes 51: 1805-1814.
43. De Paula D, Bentley MV, Mahato RI, (2007) Effect of iNOS and NF-kappaB gene silencing on beta-cell survival and function. J Drug Target 15: 358-369.
44. Hagerkvist R, Sandler S, Mokhtari D, Welsh N, (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. Faseb J 21: 618-628.
45. Chang I, Kim S, Kim JY, Cho N, Kim YH, et al. (2003) Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis. Diabetes 52: 1169-1175.
46. Maedler K, Schumann DM, Sauter N, Ellingsgaard H, Bosco D, et al. (2006) Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes 55: 2713-2722.
47. Hammar EB, Irminger JC, Rickenbach K, Parnaud G, Ribaux P, et al. (2005) Activation of NF-kappaB by extracellular matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic beta cells. J Biol Chem 280: 30630-30637.
48. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA, (2010) Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 21: 261-267.
49. Romagnani P, Crescioli C, (2012) CXCL10: A candidate biomarker in transplantation. Clin Chim Acta 413: 1364-1373.
50. Uno S, Imagawa A, Saisho K, Okita K, Iwahashi H, et al. (2012) Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes. Endocr J 57: 991-996.
51. Morimoto J, Yoneyama H, Shimada A, Shigihara T, Yamada S, et al. (2004) CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol 173: 7017-7024.